The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2
Open Access
- 31 December 2022
- journal article
- research article
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 13 (6) , 443-447
Abstract
Objectives: On November 5, 2021, Pfizer Inc. announced Paxlovid (nirmatrelvir+ritonavir) as a treatment method that could reduce the risk of hospitalization or death for patients with confirmed coronavirus disease 2019 (COVID-19).Methods: From February 6, 2022 to April 2, 2022, the incidence of COVID-19 and the effects of treatment with Paxlovid were analyzed in 2,241 patients and workers at 5 long-term care facilities during the outbreak of the Omicron variant of severe acute respiratory syndrome coronavirus 2 in South Korea.Results: The rate of severe illness or death in the group given Paxlovid was 51% lower than that of the non-Paxlovid group (adjusted risk ratio [aRR], 0.49; 95% confidence interval [CI], 0.24−0.98). Compared to unvaccinated patients, patients who had completed 3 doses of the vaccine had a 71% reduced rate of severe illness or death (aRR, 0.29; 95% CI, 0.13−0.64) and a 65% reduced death rate (aRR, 0.35; 95% CI, 0.15−0.79).Conclusion: Patients given Paxlovid showed a lower rate of severe illness or death and a lower fatality rate than those who did not receive Paxlovid. Patients who received 3 doses of the vaccine had a lower rate of severe illness or death and a lower fatality rate than the unvaccinated group.Keywords
This publication has 5 references indexed in Scilit:
- Effectiveness of Booster mRNA Vaccines Against SARS-CoV-2 Infection in an Elderly Population, South Korea, October 2021–January 2022Clinical Infectious Diseases, 2022
- Time from Exposure to Diagnosis among Quarantined Close Contacts of SARS-CoV-2 Omicron Variant Index Case-Patients, South KoreaEmerging Infectious Diseases, 2022
- Community Transmission of SARS-CoV-2 Omicron Variant, South Korea, 2021Emerging Infectious Diseases, 2022
- Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysisAnnals of Medicine, 2022
- Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reportsBMJ, 2021